{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:39:13Z","timestamp":1778722753221,"version":"3.51.4"},"reference-count":25,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This article has a companion Point by Mateos and Gonz\u00e1lez-Calle.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018021238","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T11:46:11Z","timestamp":1542109571000},"page":"3050-3053","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Timing of treatment of smoldering myeloma: delay until progression"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"issue":"2","key":"2020021108385343000_B1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/10428194.2017.1334124","article-title":"Diagnosis and management of smoldering multiple myeloma: the razor\u2019s edge between clonality and cancer","volume":"59","author":"Muchtar","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"2020021108385343000_B2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"24","key":"2020021108385343000_B3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"2020021108385343000_B4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood.V62.1.166.166","article-title":"Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma","volume":"62","author":"Greipp","year":"1983","journal-title":"Blood"},{"issue":"7","key":"2020021108385343000_B5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","article-title":"The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells","volume":"17","author":"L\u00f3pez-Corral","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2020021108385343000_B6","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"2020021108385343000_B7","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"2020021108385343000_B8","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2020021108385343000_B9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"2020021108385343000_B10","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021108385343000_B11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2020021108385343000_B12","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2020021108385343000_B13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fern\u00e1ndez de Larrea","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2020021108385343000_B14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3324\/haematol.2015.124651","article-title":"Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)","volume":"100","author":"Khan","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"2020021108385343000_B15","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2020021108385343000_B16","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"issue":"3","key":"2020021108385343000_B17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/leu.2014.313","article-title":"Classifying ultra-high risk smoldering myeloma","volume":"29","author":"Waxman","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2020021108385343000_B18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2020021108385343000_B19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"2020021108385343000_B20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.21821","article-title":"Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma","volume":"85","author":"Detweiler-Short","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"2020021108385343000_B21","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2020021108385343000_B22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.23159","article-title":"Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study","volume":"87","author":"Golombick","year":"2012","journal-title":"Am J Hematol"},{"issue":"6","key":"2020021108385343000_B23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"2020021108385343000_B24","article-title":"Assessment of safety and immunogenicity of PVX-410 vaccine with or without lenalidomide in patients with smoldering multiple myeloma: a nonrandomized clinical trial [published online ahead of print 16 August 2018]","author":"Nooka","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"2020021108385343000_B25","first-page":"402","article-title":"Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd [abstract]","volume":"130","author":"Mateos","year":"2017","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/21\/3050\/1629704\/advances021238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/21\/3050\/1629704\/advances021238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:11:39Z","timestamp":1581412299000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/21\/3050\/16162\/Timing-of-treatment-of-smoldering-myeloma-delay"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":25,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,11,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018021238","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]}}}